Driving Innovation Through Treg Data & Antigen Targeting to Unlock Treg Therapeutic Potential

Time: 3:15 pm
day: Conference Day Two P2

Details:

• Utilize polyclonal Treg data to guide therapeutic direction and inform next-generation cell therapy design
• Highlight PolTREG and Immuthera’s latest Type 1 Diabetes findings to demonstrate clinical progress and therapeutic potential
• Advance disease-specific Treg therapies by leveraging antigen-driven precision for durable immune modulation

Speakers:

Daniel Shelly Daniel Shelly is a member of the Executive Leadership Team at PolTREG, where he leads efforts to advance next-generation T-regulatory cell therapies for autoimmune diseases. Read more